Trial Profile
A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 MG QD to Placebo as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Sep 2021
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 28 Feb 2011 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
- 13 Nov 2008 Status changed from active, no longer recruiting to completed, as reported by clinicaltrials.gov.
- 12 Sep 2008 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met.